Tazemetostat: Targeting EZH2 in R/R Follicular Lymphoma

Opinion
Video

Hematologist/oncologists describe the rationale for treatment approaches targeting EZH2 and discuss recent guideline updates surrounding the role of tazemetostat and EZH2 testing in patients with follicular lymphoma.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Navigating Treatment Choices in R/R FL: Patient Values and Shared Decision-Making
      Navigating Treatment Choices in R/R FL: Patient Values and Shared Decision-Making
      Assessing CAR T and Bispecifics for R/R FL: Identifying the Right Candidates & Factoring in CD20 and CD19 Negativity or Positivity
      Assessing CAR T and Bispecifics for R/R FL: Identifying the Right Candidates & Factoring in CD20 and CD19 Negativity or Positivity
      Managing Epithelioid Sarcoma: Follow-Up Strategies and Treatment Decisions for Stable Disease vs Progression
      Managing Epithelioid Sarcoma: Follow-Up Strategies and Treatment Decisions for Stable Disease vs Progression
      Navigating Frontline Therapy in Epithelioid Sarcoma: Key Clinical Considerations and Shared Decision-Making
      Navigating Frontline Therapy in Epithelioid Sarcoma: Key Clinical Considerations and Shared Decision-Making
      CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
      Highlighting “Trickle Down” Progress in Developing Rare Lymphoma Treatment
      Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation
      Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation
      Institutional Implementation: Setting Up Tarlatamab Administration
      Institutional Implementation: Setting Up Tarlatamab Administration
      The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
      Perseverance Underscores Success in Rare Lymphoma Research
      Choosing Between Tazemetostat and Zanubrutinib+Obinutuzumab: Key Factors & Patient Conversations
      Choosing Between Tazemetostat and Zanubrutinib+Obinutuzumab: Key Factors & Patient Conversations
      Expert Perspectives: Tazemetostat in R/R FL
      Expert Perspectives: Tazemetostat in R/R FL
      Related Content
      The FDA originally placed a clinical hold on the program for tab-cel in January 2025 due to Good Manufacturing Practice (GMP) compliance issues associated with a pre-license inspection of a third-party manufacturing facility.

      FDA Lifts Clinical Hold on Tabelecleucel in EBV+ Lymphoproliferative Disease

      Russ Conroy
      May 7th 2025
      Article

      Investigators can restart the phase 3 ALLELE trial assessing tabelecleucel for patients with EBV-related posttransplant lymphoproliferative disease.

      Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

      Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

      Viviana Cortiana, MS4;Yan Leyfman, MD
      May 12th 2025
      Podcast

      Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

      CHMP Recommends Brentuximab Vedotin/Chemo in Advanced Hodgkin Lymphoma

      CHMP Recommends Brentuximab Vedotin/Chemo in Advanced Hodgkin Lymphoma

      Tim Cortese
      April 25th 2025
      Article

      Results from the phase 3 HD21 trial showed that brentuximab vedotin plus chemotherapy was superior to alternative treatments in Hodgkin lymphoma.

      Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

      Highlighting Insights From the Marginal Zone Lymphoma Workshop

      Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
      February 17th 2025
      Podcast

      Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

      Diagnostic developments using aberrances in biomarker testing may help enhance survival in patients with rare lymphoma subtypes.

      Elucidating the Clinical Landscape for Rare Lymphoma Treatment

      Roman Fabbricatore
      April 17th 2025
      Article

      Diagnostic developments using aberrances in biomarker testing may help enhance survival in patients with rare lymphoma subtypes.

      Synthetic Hypericin Achieves Treatment Success in Cutaneous T-Cell Lymphoma

      Synthetic Hypericin Achieves Treatment Success in Cutaneous T-Cell Lymphoma

      Tim Cortese
      April 16th 2025
      Article

      At the indication of the FDA and EMA, the phase 3 FLASH2 trial will further evaluate synthetic hypericin in early-stage cutaneous T-cell lymphoma.